Márk Plander

Márk Plander

Auto-generated profile, based on publicly available information

Márk Plander

Department of Hematology and Hemostaseology, Vas County Markusovszky University Hospital, 9700 Szombathely, Hungary

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 April 2011 in Annals of Hematology
Verified
Journal Article
Closed access
PDF file
MPMárk Plander
Márk Plander
PUPeter Ugocsai
Peter Ugocsai
SSSilvia Seegers
Silvia Seegers
EOEvelyn Orsó
Evelyn Orsó
ARAlbrecht Reichle
Albrecht Reichle
GBGero Brockhoff
Gero Brockhoff

Verified
Journal Article
Open access
PDF file
LKLili Kotmayer
Lili Kotmayer
TLTamás László
Tamás László
Gabor MikalaGabor Mikala
Gabor Mikala
RKRichárd Kiss
Richárd Kiss
LLLuca Lévay
Luca Lévay
DADonat Alpar
Donat Alpar
The oral, highly selective Bcl2 inhibitor venetoclax has substantially improved the therapeutic landscape of chronic lymphocytic leukemia (CLL). Despite the remarkable response rates in patients with relapsed/refractory (R/R) disease, acquired resistance is the leading cause of treatment failure, with somatic BCL2 mutations being the predominant genetic drivers underpinning venetoclax resistance. To assess the correlation between disease progression and the most common BCL2 mutations G101V and D103Y, sensitive (10−4) screening for the most common BCL2 mutations G101V and D103Y was performed in 67 R/R CLL patients during venetoclax single-agent or venetoclax–rituximab combination therapy. With a median follow-up time of 23 months, BCL2 G101V and D103Y were detected in 10.4% (7/67) and 11.9% (8/67) of the cases, respectively, with four patients harboring both resistance mutations. Ten out of eleven patients carrying BCL2 G101V and/or D103Y experienced relapse during the follow-up period, representing 43.5% of the cases (10/23) showing clinical signs of disease progression. All BCL2 G101V or D103Y variants were detected in patients receiving venetoclax as a continuous single-agent treatment while these mutations were not observed during or after fixed-duration venetoclax therapy. Targeted ultra-deep sequencing of BCL2 uncovered three additional variants in four patient samples obtained at relapse, suggesting convergent evolution and implying a cooperating role of BCL2 mutations in driving venetoclax resistance. This cohort is the largest R/R CLL patient population reported to date in which BCL2 resistance mutations were investigated. Our study demonstrates the feasibility and clinical value of sensitive screening for BCL2 resistance mutations in R/R CLL.

15 April 2015 in Annals of Hematology
Verified
Journal Article
Closed access
PDF file
MPMark Plander
Mark Plander
TSTamás Szendrei
Tamás Szendrei
IBImre Bodó
Imre Bodó
JIJános L. Iványi
János L. Iványi

25 October 2018 in Pathology and Oncology Research
Verified
Journal Article
Closed access
PDF file
MPMark Plander
Mark Plander
TSTamás Szendrei
Tamás Szendrei
ÁVÁrpád Vadvári
Árpád Vadvári
JIJános Iványi
János Iványi

8 July 2024 in Pathology and Oncology Research
Verified
Journal Article
Open access
PDF file
MPMárk Plander
Márk Plander
MKMária Kányási
Mária Kányási
TSTamás Szendrei
Tamás Szendrei
JSJudit Skrapits
Judit Skrapits
BTBotond Timár
Botond Timár
Background: Myelodysplastic neoplasms (MDS) are characterized by cytopenia, morphologic dysplasia, and genetic abnormalities. Multiparameter flow cytometry (FCM) is recommended in the diagnostic work-up of suspected MDS, but alone is not sufficient to establish the diagnosis. Our aim was to investigate the diagnostic power of FCM in a heterogeneous population of patients with cytopenia, excluding cases with increased blast count.Methods: We analyzed bone marrow samples from 179 patients with cytopenia (58 MDS, 121 non-MDS) using a standardized 8-color FCM method. We evaluated the sensitivity, specificity, and accuracy of several simple diagnostic approaches, including Ogata score, extended Ogata score, the WHO and ELN iMDSFlow recommended “3 aberrations in two cell compartments method,” and the combination of the Ogata score and “3 aberrations in two cell compartments method.” The patients were followed until the diagnosis was confirmed, with a median follow-up of 2 months (range 0.2–27).Results: The combination of Ogata score and “3 aberrations in two cell compartments method” achieved the highest diagnostic accuracy (78%) with sensitivity and specificity 61% and 86%, respectively. When using only the “3 aberrations in two cell compartments method,” the accuracy was 77% with a sensitivity of 72% and a specificity of 79%. The most frequently observed etiologies among the false positive cases were substrate deficiencies, inflammation/infection, or toxic effects. MDS can be excluded in all these cases after a thorough clinical evaluation and a relatively short follow-up.Conclusion: FCM remains an important but supplementary part in an integrated diagnostic process of MDS with low blasts. The combination of the Ogata score and the “3 aberrations in two cell compartments method” slightly improves accuracy compared to the detection of “3 aberrations in two cell compartments method” alone.

22 April 2021 in Pathology and Oncology Research
Verified
Journal Article
Open access
PDF file
GVGergely Varga
Gergely Varga
ATAndrás Dávid Tóth
András Dávid Tóth
VSVirág Réka Szita
Virág Réka Szita
ZCZoltán Csukly
Zoltán Csukly
AHApor Hardi
Apor Hardi
Gabor MikalaGabor Mikala
Gabor Mikala
In Hungary, the cost of lenalidomide-based therapy is covered only for relapsed multiple myeloma (MM) patients, therefore lenalidomide is typically used in the second-line either as part of a triplet with proteasome inhibitors or as a doublet. Lenalidomide-dexamethasone is a standard treatment approach for relapsed/refractory MM, and according to recent large randomized clinical trials (RCT, the standard arm of POLLUX, ASPIRE, TOURMALINE), the progression-free survival (PFS) is expected to be approximately 18 months. We surveyed ten Hungarian centers treating MM and collected data of 278 patients treated predominantly after 2016. The median age was 65 years, and patients were distributed roughly equally over the 3 international staging system groups, but patients with high risk cytogenetics were underrepresented. 15.8% of the patients reached complete response, 21.6% very good partial response, 40.6% partial response, 10.8% stable disease, and 2.5% progressed on treatment. The median PFS was unexpectedly long, 24 months, however only 9 months in those with high risk cytogenetics. We found interesting differences between centers regarding corticosteroid type (prednisolone, methylprednisolone or dexamethasone) and dosing, and also regarding the choice of anticoagulation, but the outcome of the various centers were not different. Although the higher equivalent steroid dose resulted in more complete responses, the median PFS of those having lower corticosteroid dose and methylprednisolone were not inferior compared to the ones with higher dose dexamethasone. On multivariate analysis high risk cytogenetics and the number of prior lines remained significant independent prognostic factors regarding PFS (p < 0.001 and p = 0.005). Our results show that in well-selected patients Lenalidomide-dexamethasone can be a very effective treatment with real-world results that may even outperform those reported in the recent RCTs. This real world information may be more valuable than outdated RCT data when treatment options are discussed with patients.